New direct-acting antiviral regimens are well-tolerated and produce cure rates far exceeding those of interferon-based therapy for people with decompensated cirrhosis.
Sofosbuvir + Daclatasvir + Ribavirin Cures Advanced Cirrhosis and Liver Transplant Patients (ALLY-1)
Merck Hepatitis C Combination Achieves 90% Cure in Advanced Cirrhosis Patients (C-SALT)
5/7/15